Revises provisions relating to the prevention and early detection of lung cancer. (BDR 57-68)
Summary
SB387 revises Nevada insurance law to require certain private health insurance policies and health plans that cover treatment for lung cancer to also cover screening for lung cancer. The mandate applies to a broad set of regulated products, including individual and group health insurance, health benefit plans, benefit contracts issued by societies, hospital and medical services corporation policies, health maintenance organization plans, and managed care organization plans. Coverage must follow American Cancer Society screening guidelines or other guidelines/reports from nationally recognized professional organizations based on current scientific data.
The bill also directs the Department of Health and Human Services to study whether the American Cancer Society’s lung cancer screening criteria create inequities in access based on sex or gender identity or expression, and to report findings and recommendations to the Legislature. The bill becomes effective for most purposes on January 1, 2026, with immediate effect for rulemaking and preparatory work, and it expressly excludes the new screening mandate from applying to Medicaid managed care organizations and certain Medicaid/CHIP managed care provisions.
Impact
SB387 amends multiple chapters of Nevada insurance law to create a new coverage requirement for lung cancer screening wherever a policy already covers lung cancer treatment, and it makes conflicting policy terms void for policies issued, delivered, or renewed on or after January 1, 2026. It also gives the Insurance Commissioner enforcement authority, including the ability to require the coverage in certain out-of-state policies issued by domestic insurers and to suspend or revoke certificates of authority for noncompliant health maintenance organizations and other insurers. The bill leaves Medicaid managed care organizations outside the new mandate, while preserving existing managed care exceptions in related statutes.
Sentiment
The bill appears to have been broadly supported and noncontroversial in the Legislature, passing the Senate 21-0 and the Assembly 42-0. The unanimous votes suggest strong bipartisan agreement around expanding access to preventive cancer screening and early detection. The inclusion of a study on possible inequities in screening criteria also indicates an effort to address fairness concerns without delaying the coverage expansion.
Contention
The main policy issue reflected in the bill is whether existing American Cancer Society screening criteria may disadvantage certain populations, particularly based on sex or gender identity or expression. That concern is addressed through the required DHHS study and report, rather than by changing the coverage standard immediately. Another point of distinction is the bill’s carve-out for Medicaid managed care organizations, which means the new mandate applies to most private coverage but not to those publicly administered managed care arrangements.